Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01010061
Other study ID # BO21004 (Stage 1a)
Secondary ID 2009-012476-28;
Status Completed
Phase Phase 3
First received
Last updated
Start date December 21, 2009
Est. completion date August 23, 2017

Study information

Verified date August 2018
Source Hoffmann-La Roche
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL). Patients will be randomized 2:2:1 to receive a maximum of six 28-day cycles of either RO5072759 (1000 mg intravenous (iv) infusion, on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6) plus chlorambucil (0.5 mg/kg orally, days 1 and 15 of cycles 1-6), or rituximab (iv infusion day 1, 375 mg/m^2 cycle 1, 500 mg/m^2 cycles 2-6) plus chlorambucil, or chlorambucil alone. Anticipated time on study treatment is >6 months and follow-up for disease-progression and safety will be at least 5 years. In the US, this trial is sponsored/managed by Genentech.


Description:

Protocol BO21004 is divided into 3 separate Unique Protocol IDs for reporting results on clinicaltrials.gov because there are 3 separate primary analyses conducted at different time-points.

- BO21004 (Stage 1a) [NCT01010061] includes the analysis of 2 of the 3 arms obinutuzumab plus chlorambucil (Glb) compared to chlorambucil (Clb) reported here.

- BO21004 (Stage 1b) [NCT01998880] includes the analysis of 2 of the 3 arms rituximab plus chlorambucil (RClb) compared to chlorambucil (Clb) reported separately.

- BO21004 (Stage 2) [NCT02053610] includes the analysis of 2 of the 3 arms obinutuzumab plus chlorambucil (Glb) compared to rituximab plus chlorambucil (RClb) reported separately.


Other known NCT identifiers
  • NCT02035462

Recruitment information / eligibility

Status Completed
Enrollment 787
Est. completion date August 23, 2017
Est. primary completion date July 1, 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adults >/=18 years

- Documented Cluster of Differentiation Antigen 20 (CD20) + B-Cell Chronic Lymphocytic Lymphoma (B-CLL)

- Previously untreated Chronic Lymphocytic Leukemia (CLL) requiring treatment according to the National Cancer Institute (NCI) criteria

- Total Cumulative Illness Rating Scale (CIRS) > 6 and/or creatinine clearance < 70 ml/min

Exclusion Criteria:

- Prior CLL therapy

- Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)

- History of other malignancy unless the malignancy has been in remission without treatment for >/=2 years prior to enrolment, and except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, surgically treated low-grade prostate cancer, or ductal carcinoma in situ (DCIS) of the breast treated with lymphectomy alone

- Positive hepatitis serology (HBV, HCV) or positive HIV or Human T Cell Leukemia Virus (HTLV) testing

- Patients with active infection requiring systemic treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
obinutuzumab
1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
rituximab
375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
chlorambucil
Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Hoffmann-La Roche Genentech, Inc., German CLL Study Group

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Brazil,  Bulgaria,  Canada,  Croatia,  Czechia,  Denmark,  Egypt,  Estonia,  France,  Germany,  Hong Kong,  Italy,  Mexico,  Netherlands,  New Zealand,  Romania,  Russian Federation,  Slovakia,  Spain,  Switzerland,  Thailand,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free Survival (PFS) PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the investigator. Progressive disease (PD) required at least one of the following: =50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (>15 mm in longest diameter) or any new extra nodal lesion, =50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, =50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels >20 g/L or <10 g/dL or a decrease of platelet counts >50% or <100 x 10^9/L or by a decrease of neutrophil counts >50% or <1.0 x 10^9/L). Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Primary Percentage of Participants With Progression Free Survival Events Percentage of Participants with Progression Free Survival Events: disease progression, relapse, or death. Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Secondary Progression Free Survival Based on Independent Review Committee (IRC) Data PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by Independent Review Committee. Progressive disease required at least one of the following: =50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (>15 mm in longest diameter) or any new extra nodal lesion, =50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, =50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels >20 g/L or <10 g/dL or a decrease of platelet counts >50% or <100 x 10^9/L or by a decrease of neutrophil counts >50% or <1.0 x 10^9/L). Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)
Secondary Percentage of Participants With Progression Free Survival Events Based on Independent Review Committee (IRC) Data Percentage of Participants with Progression Free Survival Events: progression, relapse, or death from any cause as assessed by an Independent Review Committee. Randomization to clinical cutoff date of 9 May 2013 (median observation 22.8 months)
Secondary Percentage of Participants With End of Treatment Response (EOTR) EOTR was the first response assessment 56 days from the last dose according to the International Workshop on Chronic Lymphocytic Leukaemia (IWCLL) guidelines. CR required: Peripheral blood lymphocytes below 4 x 10^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils >1.5 x 10^9/L, Platelets >100 x 10^9/L, Hemoglobin >11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: =50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a = 50% reduction in lymphadenopathy OR =50% reduction of liver enlargement OR =50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils >1.5 x 10^9/ or =50% increase, Platelets >100 x 10^9/L or =50% increase, Hemoglobin 11 g/dL or =50% increase. Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Secondary Percentage of Participants With Best Overall Response Best overall response according to IWCLL guidelines was defined as the percentage of patients with CR, CRi,PR or nPR. CR required all of the following: Peripheral blood lymphocytes below 4 x 10^9/L, Absence of significant lymphadenopathy, No hepatomegaly, No splenomegaly, Absence of disease, Blood counts above the following values (Neutrophils >1.5 x 10^9/L, Platelets >100 x 10^9/L, Hemoglobin >11g/dL) and Bone marrow at least normocellular for age. CRi was CR with incomplete bone marrow recovery. PR required the following for at least 2 months from end of treatment: =50% decrease in peripheral blood lymphocyte count from the pre-treatment value AND Either a = 50% reduction in lymphadenopathy OR =50% reduction of liver enlargement OR =50% reduction of spleen enlargement PLUS at least one of the following: Neutrophils >1.5 x 10^9/ or =50% increase, Platelets >100 x 10^9/L or =50% increase, Hemoglobin 11 g/dL or =50% increase. Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Secondary Event Free Survival Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progressive disease as per IWCLL criteria required at least one of the following: =50% increase in the absolute number of lymphocytes, appearance of new palpable lymph nodes (>15 mm in longest diameter) or any new extra nodal lesion, =50% increase in the longest diameter of any previous site of clinically significant lymphadenopathy, =50% increase in the enlargement of the liver and/or spleen, Transformation to a more aggressive histology or After treatment, the progression of any cytopenia (a decrease of hemoglobin levels >20 g/L or <10 g/dL or a decrease of platelet counts >50% or <100 x 10^9/L or by a decrease of neutrophil counts >50% or <1.0 x 10^9/L). Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Secondary Overall Survival Overall Survival (OS) was defined as the time between the date of randomization and the date of death due to any cause. Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Secondary Duration of Response Duration of Response was defined as the date the response [either Complete Response (CR) or Partial Response (PR)] was first recorded until the date of Disease Progression or death due to any cause. Response was assessed according IWCLL guidelines. Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Secondary Percentage of Participants With Molecular Remission at the End of Treatment Molecular remission was defined as a minimal residual disease (MRD)-negative result at the end of treatment (assessment that occurred between 56 days and 6 months of last treatment). Molecular remission was assessed for all patients using a blood sample. Additionally, a bone marrow sample was obtained from patients whom the investigator assumed to have a complete response, consistent with the IWCLL guidelines. A combined analysis of blood and bone marrow results was conducted. A patient was considered MRD negative if result was less than 1 chronic lymphocytic leukemia (CLL) cell in 10000 leukocytes (MRD value < 0.0001) based on the method of allele specific polymerase chain reaction (ASO-PCR). Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Secondary Time to Re-Treatment/New-antileukemic Therapy Time to re-treatment/new anti-leukemic therapy was defined as time between the date of randomization and the date of first intake of re-treatment or new anti-leukemic therapy. Randomization to clinical cutoff date of 10 Oct 2017 (median observation 62.5 months from randomization)
Secondary Pharmacokinetics of Obinutuzumab (RO5072759) in Combination With Chlorambucil (Clb) Blood samples were collected from all patients allocated to the GClb treatment arm pre- and post-dose Day 1 of Cycles 1 to 6 and were sent to a laboratory. The concentration of obinutzumab in serum was determined using a validated enzyme-linked immunosorbent assay (ELISA) and was reported in micrograms/milliliter (µg/mL). Pre- and post-dose sampling on day 1 of cycles 1-6 (Up to 26.8 months)
Secondary European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Questionnaire Score The EORTC Quality of Life Questionnaire QLQ-C30 was used to assess patient-reported outcomes (PRO) and symptom burden. The QLQ-C30 contains 30 items including the functional scales of physical functioning (5 items), role functioning (2 items), emotional functioning (4 items), cognitive functioning (2 items), social functioning (2 items) and symptom scales including fatigue (3 items), nausea and vomiting (2 items), and pain (4 items) and six single item scales on dyspnea, sleep disturbance, appetite loss, constipation, diarrhea and financial impact. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement. Baseline and Cycle 4 Day 1 (Cy4D1)
Secondary European Organization for Research and Treatment of Cancer (EORTC) QLQ-CLL16 Questionnaire Score EORTC Quality of Life Questionnaire (QLQ-CLL16) module was used to assess patient-reported outcomes and symptom burden. The QLQ-CLL16 module includes three multi-item scales assessing fatigue (2 items), treatment side effects and disease symptoms (8 items), infection (4 items) and two single item scales on social activities and future health worries. Final scores are transformed such that they range from 0 - 100, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be of minimally important difference to participants. A positive change from Baseline indicated improvement. Baseline and Cycle 4 Day 1 (Cy4D1)
See also
  Status Clinical Trial Phase
Completed NCT01072240 - An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia N/A
Completed NCT00754650 - A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia Phase 2
Active, not recruiting NCT02500407 - A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Phase 1/Phase 2
Recruiting NCT04704323 - CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Active, not recruiting NCT01414205 - A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE) Phase 2
Completed NCT01224093 - An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC) N/A
Completed NCT01395615 - An Observational Study on The Health Related Quality of Life in Patients With Chronic Lymphocytic Leukaemia N/A
Completed NCT00532129 - A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Chronic Lymphocytic Leukemia. Phase 2
Completed NCT02013817 - CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy Phase 2
Completed NCT01685892 - A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia Phase 1
Completed NCT00738374 - A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia. Phase 2
Completed NCT00241358 - Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies Phase 1/Phase 2
Completed NCT01056510 - A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Phase 4
Completed NCT01300247 - A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON) Phase 1
Terminated NCT01271010 - A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Phase 4
Completed NCT00718549 - A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL) Phase 3
Completed NCT01263704 - A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia Phase 2
Completed NCT00431873 - A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia Phase 2
Completed NCT01178086 - A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
Terminated NCT02292225 - Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) Phase 1